Actively Recruiting
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Led by Pardis Noor Medical Imaging and Cancer Center · Updated on 2025-11-25
40
Participants Needed
1
Research Sites
47 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Trans arterial chemoembolization (TACE) has emerged as a treatment option for chemotherapy-refractory diseases in Liver metastases. By delivering chemotherapy agents directly to the tumor site, TACE can maximize local drug concentrations and reduce systemic adverse reactions. Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor. It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A). The application of Bevacizumab during TACE has not been reported. In this study, we will evaluate the the overall survival (OS)、efficacy, and safety of the application of Bevacizumab during TACE in patients with Liver Metastases by designing an open, single-arm phase II clinical study.
CONDITIONS
Official Title
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed metastatic liver cancer by biopsy or characteristic imaging with no option for surgery
- ECOG performance status of 0 or 1
- Liver function classified as Child-Pugh class A or B
- Stable non-liver metastases such as bone, lung, or lymph nodes
- Liver tumor burden less than 70%
- Expected survival longer than 6 months
- Laboratory results with platelet count >50 x10^9/L, hemoglobin >8.0 g/dL, ANC ≥1.5 x10^9/L, bilirubin <51 mmol/L, ALT and AST less than 3 times upper normal limit, serum creatinine <1.5 times upper normal limit
You will not qualify if you...
- Active infection
- Severe health problems including hepatic encephalopathy, refractory ascites, or esophageal variceal bleeding
- Previous liver surgery
- Prior TACE treatment at other centers
- Poor performance status with ECOG > 1
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pardis Noor Medical Imaging and Cancer Center
Tehran, Tehran Province, Iran, 021
Actively Recruiting
Research Team
S
Shahram Akhlaghpoor, M.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here